Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart,NovoRapid®,and fast insulin aspart, Fiasp®, has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual...
Advancing today's therapies to enable healthier lives.
Telephone: +44 (0)1223 426 060
Chesterford Research Park Little Chesterford Saffron Walden
Post Code: CB10 1XL
Country: United Kingdom
Membership Type: Corporate 21-50